Pooling overdispersed binomial data to estimate event rate
暂无分享,去创建一个
[1] Griffiths Da. Maximum likelihood estimation for the beta-binomial distribution and an application to the household distribution of the total number of cases of a disease. , 1973 .
[2] A. Woscoff,et al. Itraconazole versus terbinafine (LAMISIL®): which is better for the treatment of onychomycosis? , 1997 .
[3] B. Piraccini,et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. , 1996, Journal of the American Academy of Dermatology.
[4] H. Zaun,et al. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. , 1995, Archives of dermatology.
[5] David M. Drukker,et al. On boundary-value likelihood-ratio tests , 2001 .
[6] M. Bräutigam,et al. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group. , 1995, Journal of the American Academy of Dermatology.
[7] The statistical power of replications in difference tests , 2003 .
[8] D. Bates,et al. Newton-Raphson and EM Algorithms for Linear Mixed-Effects Models for Repeated-Measures Data , 1988 .
[9] T. Louis,et al. Bayes and Empirical Bayes Methods for Data Analysis. , 1997 .
[10] L. Dubertret,et al. Comparative multicentre double-blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis , 1997 .
[11] V. Voravutinon. Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. , 1993, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[12] M. De Backer,et al. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. , 1998, Journal of American Academy of Dermatology.
[13] R. Hay,et al. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 1OO mg/day in plantar‐type tinea pedis , 1995, The British journal of dermatology.
[14] Martin Jansche,et al. Parametric Models of Linguistic Count Data , 2003, ACL.
[15] T. Kurth,et al. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. , 2007, The American journal of medicine.
[16] J. Leyden,et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. , 1997, Journal of the American Academy of Dermatology.
[17] N. Zaias,et al. Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind, placebo-controlled trial. , 1990, Journal of the American Academy of Dermatology.
[18] E. Alpsoy,et al. Intermittent Therapy with Terbinafine for Dermatophyte Toe‐Onychomycosis: A New Approach , 1996, The Journal of dermatology.
[19] Tom Leonard,et al. A Bayesian Approach to Some Multinomial Estimation and Pretesting Problems , 1977 .
[20] J. Czernielewski,et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region , 2000, The British journal of dermatology.
[21] B. L. Andersen,et al. Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months' follow-up. , 1997, Acta dermato-venereologica.
[22] C. Lynde,et al. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. , 2001, Journal of the American Academy of Dermatology.
[23] D. Ennis,et al. THE BETA‐BINOMIAL MODEL: ACCOUNTING FOR INTER‐TRIAL VARIATION IN REPLICATED DIFFERENCE AND PREFERENCE TESTS , 1998 .
[24] M. Crijns,et al. A randomized treatment duration‐finding study of terbinafine in onychomycosis , 1992, The British journal of dermatology.
[25] Aditya K. Gupta,et al. Efficacy of Itraconazole, Terbinafine, Fluconazole, Griseofulvin and Ketoconazole in the Treatment of Scopulariopsis brevicaulis Causing Onychomycosis of the Toes , 2001, Dermatology.
[26] Yuhlong Lio,et al. A note on bayesian estimation and prediction for the beta-binomial model , 1999 .
[27] L. I. Díez,et al. A comparative double‐blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris , 1990 .
[28] R. Savin. Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil) , 1989, Clinical and experimental dermatology.
[29] R. Schopf,et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection , 1995, BMJ.
[30] Christy Chuang-Stein,et al. An Application of the Beta-Binomial Model to Combine and Monitor Medical Event Rates in Clinical Trials , 1993 .
[31] Nagaraj K. Neerchal,et al. Large cluster results for two parametric multinomial extra variation models , 1998 .
[32] G. Levy,et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. , 1998, International journal of dermatology.
[33] E. Evans,et al. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. , 1999, BMJ.
[34] D. Massart,et al. Two‐week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double‐blind, multicentre study , 1994, The British journal of dermatology.
[35] A. Rukhin. Bayes and Empirical Bayes Methods for Data Analysis , 1997 .
[36] D. Griffiths. Maximum likelihood estimation for the beta-binomial distribution and an application to the household distribution of the total number of cases of a disease. , 1973, Biometrics.
[37] 角田 亮子,et al. プロダクトレビュー Lippincott Williams & Wilkinsの電子ジャーナル , 2007 .
[38] David R. Cox,et al. Some remarks on overdispersion , 1983 .
[39] H. Degreef,et al. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. , 1999, Acta dermato-venereologica.
[40] A. Akar,et al. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis , 2002, The Journal of dermatological treatment.
[41] Joel C. Kleinman,et al. Proportions with Extraneous Variance: Single and Independent Samples , 1973 .
[42] S. López Gómez,et al. A comparative double‐blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris , 1990, Clinical and experimental dermatology.
[43] P. Nordin,et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. , 1995, Journal of the American Academy of Dermatology.
[44] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[45] E. Evans,et al. Treatment of dermatophyte infection of the finger‐ and toe‐nails with terbinafine (SF 86‐327, Lamisil), an orally active fungicidal agent , 1989, The British journal of dermatology.
[46] E. Evans,et al. Short term treatment of dermatophyte onychomycosis with terbinafine. , 1992, BMJ.
[47] R. Arenas,et al. OPEN RANDOMIZED COMPARISON OE ITRACONAZOLE VERSUS TERBINAEINE IN ONYCHOMYCOSIS , 1995, International journal of dermatology.
[48] B. Sigurgeirsson,et al. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis , 1999 .
[49] R. Tarone,et al. Testing the goodness of fit of the binomial distribution , 1979 .
[50] J. G. Skellam. A Probability Distribution Derived from the Binomial Distribution by Regarding the Probability of Success as Variable between the Sets of Trials , 1948 .
[51] Paulo Guimarães. A Simple Approach to Fit the Beta-binomial Model , 2005 .
[52] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[53] Peter Congdon,et al. Applied Bayesian Modelling , 2003 .
[54] D. Hogan. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. , 1995, Journal of the American Academy of Dermatology.
[55] S. Paul. Analysis of proportions of affected foetuses in teratological experiments. , 1982, Biometrics.
[56] M. Bräutigam,et al. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double‐blind trial comparing 6 and 12 weeks therapy , 1997, The British journal of dermatology.
[57] Jack C. Lee,et al. Bayesian Estimation and Prediction for the Beta-Binomial Model , 1987 .
[58] J. Marley,et al. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. , 1995, Journal of the American Academy of Dermatology.
[59] Robert L. Strawderman,et al. Use of the Probability Integral Transformation to Fit Nonlinear Mixed-Effects Models With Nonnormal Random Effects , 2006 .
[60] W W Piegorsch,et al. On a Likelihood‐Based Goodness‐of‐Fit Test of the Beta‐Binomial Model , 2000, Biometrics.
[61] Dorothy A. Anderson. SOME MODELS FOR OVERDISPERSED BINOMIAL DATA , 1988 .
[62] T. Rantanen,et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil®) with fluconazole (Diflucan®) in the treatment of onychomycosis , 2000, The British journal of dermatology.
[63] T. Kurth,et al. The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. , 2008, Lung cancer.
[64] K Y Liang,et al. On testing departure from the binomial and multinomial assumptions. , 1989, Biometrics.
[65] E. Warshaw,et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. , 2005, Journal of the American Academy of Dermatology.
[66] S. Avner,et al. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis , 2005, The Journal of dermatological treatment.